A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of two dose levels of RO4989991 Administered Subcutaneously to Patients with Allergic Rhinitis

Trial Profile

A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of two dose levels of RO4989991 Administered Subcutaneously to Patients with Allergic Rhinitis

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Oxelumab (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Jan 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top